Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Dmitry P. Udovitsa"'
Autor:
Tatiana I. Prokopenko, Roman Ivanov, Sergiy Alekseev, Julia S. Shapovalova, Olga Filon, Dmitry P. Udovitsa, Mikhail V. Kopp, Irina A. Jelvakova, Olga Burdaeva, Sergei Tjulandin, Marina Stenina, Mona Frolova, Ludmila P. Sheveleva, Daniil L. Stroyakovsky, Ekaterina Ignatova, Marina Nechaeva, Andrey V. Khorinko, Bogdan Kotiv
Publikováno v:
Journal of Clinical Oncology. 32:e11576-e11576
e11576 Background: BCD-022 is a trastuzumab biosimilar candidate manufactured by CJSC BIOCAD, Russia. Full spectrum of physicochemical and preclinical studies showed equivalence of BCD-022 to innov...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9bc53d722207e7a75790ab314707e576
https://doi.org/10.1200/jco.2014.32.15_suppl.e11576
https://doi.org/10.1200/jco.2014.32.15_suppl.e11576
Autor:
Martina Uttenreuther-Fischer, Tamas Hickish, Chiun-Sheng Huang, Nadezhda V. Kovalenko, Dmitry P. Udovitsa, K Pelling, Janice Tsang, Ling-Ming Tseng, Ajay O. Mehta
Publikováno v:
Journal of Clinical Oncology. 30:TPS651-TPS651
TPS651 Background: Management of HER2-overexpressing MBC has improved over the past decade. However, pts still develop resistance to currently available HER2-targeted therapies and novel effective treatments are increasingly required as dual targeted
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e43145026339476c7fa714b4c7926304
https://doi.org/10.1200/jco.2012.30.15_suppl.tps651
https://doi.org/10.1200/jco.2012.30.15_suppl.tps651